Plus some worthwhile comments from AZ's Soriot on the company's IRA approach
Plus Optum is making insulins more accessible
And a 340B decision is elevating the definition of 'patient'
And there's a new AARP poll coming on the importance of drug prices on voters
Plus lots of thinking about the future of gene therapy today
And some perspective on the interesting PBM language floating around the Senate
And a new ICER effort falls short (even ICER thinks so)
And the CMS effort to gather patient input just looks worse and worse
And the quote of the week, from Zeke Emanuel: "The system sucks worse than ever."
And I have some issues with a new WaPo op-ed
And AbbVie puts a number on the IRA impact
And earnings calls have been notably quiet on policy discussions
